TEM Stock Chart & Stats
$756.00
-$61.00(-7.47%)
―
--
Day’s Range― - ―
52-Week Range$735.01 - $1,905.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)583.00
Market Cap
$134.54B
Enterprise ValueN/A
Total Cash (Recent Filing)$639.07M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta1.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares OutstandingN/A
10 Day Avg. Volume332
30 Day Avg. Volume583
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,151.54Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Improving Unit EconomicsMaterial revenue scale and a ~72% gross margin indicate improving unit economics that support operating leverage. Over 2–6 months this scaling can enable funding of platform investments, absorb fixed costs, and improve odds of sustainable profitability as diagnostics and data mix grow.
Durable Data & Contract VisibilityRapid growth in data/applications revenue and recurring multi‑year pharma contracts create predictable, high-margin revenue streams. Strong TCV and big pharma collaborations bolster long-term demand for Tempus' datasets, improving revenue visibility and reducing reliance on one-off clinical test volume.
Extensive Data & Strategic AcquisitionsA massive multimodal dataset plus planned integration of Personalis MRD and OneOme pharmacogenomics expands Tempus' addressable market and enhances model-building. These assets strengthen network effects and create a structural moat for AI-enabled clinical and life‑science services over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow increases reliance on financing and heightens execution risk. Over several quarters, continued cash burn can constrain investments, force dilutive or debt financing, and limit runway if growth or margin improvements underperform expectations.
Elevated LeverageMaterial debt relative to equity reduces financial flexibility during an unprofitable transition. If operating losses persist, leverage amplifies refinancing and interest risks, limits strategic optionality for M&A or capex, and places pressure on free cash flow over coming quarters.
MRD Reimbursement & Deal Execution RiskMRD growth hinges on reimbursement, regulatory timing, and successful Personalis integration. If reimbursement lags or approvals/due‑diligence issues delay the deal, scaling MRD would raise cash burn and dilute projected margins, making near‑term profitability and expected MRD contribution uncertain.
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $735.01 and its highest was $1905.00 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $134.54B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempus AI, Inc. Class A have?
Currently, no data Available
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in MX:TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,151.54 (― Downside)
$1,151.54 (― Downside)
Blogger Sentiment
Bullish
MX:TEM Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.36%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Stock 12 Month Forecast
Average Price Target
$1,151.54